Vascular Dementia Treatment Market Size Projected to Grow US$ 8.99 Billion by 2033 | Exclusive Report by Future Market Insights, Inc.
April 10, 2023 21:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, April 10, 2023 (GLOBE NEWSWIRE) -- According to a recent report published by Future Market Insights, The projected growth for vascular dementia treatment market indicates an increase in...
InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions
September 30, 2022 06:00 ET
|
InvestmentPitch Media and Resverlogix Corp.
VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s future...
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
September 28, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19...
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
August 22, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...
Resverlogix Announces Appointment of New Chief Scientific Officer
August 15, 2022 18:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr....
Pulmonary Hypertension Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight
August 01, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pulmonary Hypertension Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight DelveInsight’s pulmonary hypertension...
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
June 21, 2022 23:30 ET
|
Resverlogix Corp
CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary,...
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
June 08, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D...
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
May 09, 2022 07:15 ET
|
Resverlogix Corp
CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug...
Resverlogix Announces One-Year Extension of Debenture
April 19, 2022 17:05 ET
|
Resverlogix Corp
CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0 million...